NEW YORK, May 20 (Reuters) - A U.S. group is trying to block patents in five countries for Gilead Sciences Inc 's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions.
as adding to the fund's position in top holding Gilead Sciences GILD in December 2014 when concerns about a potentially ..... market-cap spectrum, mid-growth fund Eventide Gilead ETGLX at year-end 2014 held roughly 70 stocks
LOS ANGELES, April 30 (Reuters) - Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates.
April 30 (Reuters) - Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.
our $114 fair value estimate for Gilead Sciences , which reported a 52% increase ..... launch later this year, we believe Gilead 's portfolio and pipeline are diverse ..... patents begin to expire in 2018. Gilead 's $14.5 billion cash balance
April 25 (Reuters) - Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc 's Sovaldi and a commonly prescribed...
April 24 (Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc 's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders.
countries and contributing to revenues of $1 billion a year in Cuban pharmaceutical exports. YM BioSciences was acquired by Giliad Sciences in 2013, and Singapore-based Innokeys acquired its stake in the joint venture with CIMAB. Iznaga-Escobar is now chief
Feb 4 (Reuters) - Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C...
Gilead Sciences reported fourth-quarter results and ..... the next couple of years, we believe Gilead 's portfolio and pipeline are diverse ..... the firm's wide moat looks secure. Gilead 's $3.8 billion in hepatitis C revenue